Poster presented at: Global Conference on Myositis
Location and date: Potomac, MD; May 5-8, 2017
Authors: Tara Grabowsky, Jim Baker, Kirstin Lees, Cody Garges, Oodaye Shukla, Faith DeFreitas, Joanna Horobin
- The objective of the study was to assess the real-world use of oral prednisone via a closed commercial and Medicare supplemental claims database to understand the unmet need for new corticosteroid-sparing agents for patients with dermatomyositis.
- Statistical analysis was performed on the defined patient cohort using Anaconda Python.
- Approximately half of DM patients were prescribed high or low dose prednisone for 120 days or longer.
- The use of high dose prednisone was required to treat DM patients throughout all phases of their illness (pre-diagnosis, at diagnosis, and up to 5 years post diagnosis).
- One quarter of DM patients were prescribed high dose prednisone for prolonged periods of time.
- With high numbers of DM patients on chronic and high dose prednisone, the need for medications that have a steroid-sparing effect in the DM population is evident.
- These data support the urgency to develop medications that have a potential steroid-sparing effect to reduce the number of patients who could experience harmful steroid-related side effects.
- Future analyses should evaluate the incidence of corticosteroid-related adverse events and the limitations of currently used corticosteroid-sparing medications in the DM population.